Polycyclic Compounds (Compounds, Polycyclic)

1.	Lung Neoplasms (Lung Cancer) 11/01/2009 - "An improved estimate of the quantitative relationship between polycyclic hydrocarbons and lung cancer." 01/01/1990 - "Exposure to polycyclic hydrocarbons adsorbed on industrial dust was shown to significantly increase the incidence of lung cancer." 07/01/1996 - "Risks of lung cancer appeared increased for a variety of jobs throughout the complex, especially those with probable high levels of exposure to polycyclic hydrocarbons and asbestos. " 01/01/1981 - "Possible contribution of polycyclic hydrocarbons, trace metals, and gaseous pollutants to the incidence of lung cancer in the urban populations has been considered, including the role of carcinogens in the cigarette smoke. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 09/01/2004 - "Certain hazardous occupational exposures (polycyclic hydrocarbons, paints and lacquer, stone dust) may play a role in modulating tumor angiogenesis. " 09/01/1987 - "Further investigations into the effect of non-benzo ring bay-region methyl substituents on tumor-initiating activity of polycyclic hydrocarbons." 07/01/1982 - "Polycyclic hydrocarbons and cancer." 01/15/1979 - "[The problem of relationship between the exposure to polycyclic hydrocarbons and the incidence of cancer in 2 chemical plants of Thuringia]" 04/06/1978 - "The metabolism of polycyclic hydrocarbons and its relationship to cancer." Order ALL the reference details at left...
3.	Sarcoma (Soft Tissue Sarcoma) 01/01/1975 - "Specific chromosome changes in malignancy: studies in rat sarcomas induced by two polycyclic hydrocarbons." 01/01/1958 - "[Sex differences in susceptibility to production of sarcomas by polycyclic hydrocarbons in mouse XVII.]" 01/01/1982 - "Chemical carcinogens from several diverse chemical classes i.e.; aromatic amines, polycyclic hydrocarbons, nitrosamines, hormonal derivatives, metals and direct alkylating agents cause a 6.2-60.5-fold increase in the frequency of murine sarcoma virus (MSV)-induced transformation in a normal rat kidney (NRK) cell system. " Order ALL the reference details at left...
4.	Hepatocellular Carcinoma (Hepatoma) 11/01/1983 - "Activation of polycyclic hydrocarbons in Reuber H4-II-E hepatoma cells. " 09/15/1990 - "Induction of cytochrome P450IA1 in rat hepatoma cell by polycyclic hydrocarbons and a dioxin." 01/01/1982 - "We compared our data with various parameters taken from previously published results: the capacity of seven polycyclic hydrocarbons to induce aryl hydrocarbon hydroxylase (AHH) activity in human cell cultures, the capacity of 10 polycyclic hydrocarbons to induce azo dye N-demethylase activity in rat liver, the capacity of 6 polycyclic hydrocarbons to shorten zoxazolamine paralysis times in the intact rat, and the capacity of 15 benzo[a]pyrene metabolites to induce AHH activity in rat hepatoma H-4-II-E cultures. " 12/01/1990 - "Further characterization revealed the following additional differences among these three factors: (i) XF1 and XF2 could be extracted from nuclei under conditions quite different from those required for extraction of the Ah receptor; (ii) XF1 and XF2 were present in the nuclei of untreated cells and did not respond to polycyclic compounds, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and beta-napthoflavone, while nuclear Ah receptor was undetectable in untreated cells and rapidly increased in response to TCDD; (iii) inhibition of protein synthesis did not affect the TCDD-induced appearance of the Ah receptor but substantially decreased the constitutive activities of XF1 and XF2, suggesting that the Ah receptor must be present in untreated cells in an inactive form that can be rapidly activated by polycyclic compounds, while the constitutive expression of XF1 and XF2 depends on the continued synthesis of a relatively unstable protein; (iv) the receptor-deficient and nuclear translocation-defective mutants of the hepatoma cell line Hepa1, which are known to lack nuclear Ah receptor, expressed normal levels of XF1 and XF2, suggesting that the former factor is genetically distinct from the latter two; and (v) a divalent metal ion, probably Zn2+, is known to be an essential cofactor for the Ah receptor but was not required for the DNA-binding activities of XF1 and XF2. " 01/01/1982 - "differences in the rate of cellular uptake and formation of alkali-extractable metabolites of dibenzo[a,h]anthracene, 3-methylcholanthrene, and benzo[a]anthracene in Hepa-1 mouse hepatoma cell cultures do not account for differences in the capacity of these three polycyclic hydrocarbons to displace [3H]TCDD from the Ah receptor." Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 07/01/1979 - "Cell lines were established in vitro from respiratory tract carcinomas induced in rats by carcinogenic, polycyclic hydrocarbons. " 02/01/1978 - "These carcinomas were all of the squamous type and were induced by three different carcinogenic polycyclic hydrocarbons. " 01/01/2003 - "A number of carcinogens like polycyclic hydrocarbons and aromatic amines have been incriminated to induce mammary carcinomas in vitro and in vivo. " 12/01/1975 - "Hyperplasia, papilloma and carcinoma formation induced by topical application of the carcinogenic polycyclic hydrocarbons benz(a)pyrene (B(a)P) and 3-methylcholanthrene (MC) is accompanied by an increase in the mumber of A particles. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Cytochrome P-450 CYP1A1 (CYP1A1)
2.	Carcinogens
3.	Benzo(a)pyrene
4.	Amines
5.	Tetrachlorodibenzodioxin (TCDD)
6.	Methylcholanthrene
7.	DNA (Deoxyribonucleic Acid)
8.	Cytochromes
9.	Cytochrome P-450 Enzyme System (Cytochrome P450)
10.	anthracene

Best Treatments:
Research Summary Report
on Lung Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 733 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>